Use Of Preferred Providers Among Large Molecule Outsourcers

In Q32021, ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced biologic manufacturing. The data show use of preferred providers is equally likely among biologic API manufacturing as it is for biologic product manufacturing. To learn more, follow the links to the Biologic API and the Biologic Drug Product report previews.